These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27887596)

  • 1. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.
    Remschmidt C; Harder T; Wichmann O; Bogdan C; Falkenhorst G
    BMC Infect Dis; 2016 Nov; 16(1):711. PubMed ID: 27887596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
    Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
    Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
    Grabenstein JD; Manoff SB
    Vaccine; 2012 Jun; 30(30):4435-44. PubMed ID: 22542818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
    Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Won H; Kim JA; Jeong NY; Choi NK
    Vaccine; 2024 May; 42(13):3190-3196. PubMed ID: 38641496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
    Ohshima N; Nagai H; Matsui H; Akashi S; Makino T; Akeda Y; Oishi K
    Vaccine; 2014 Feb; 32(10):1181-6. PubMed ID: 24120483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of pneumococcal revaccination in patients with chronic disease.
    Davidson M; Bulkow LR; Grabman J; Parkinson AJ; Chamblee C; Williams WW; Lanier AP; Schiffman G
    Arch Intern Med; 1994 Oct; 154(19):2209-14. PubMed ID: 7944842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above].
    Ma QL; Zhang M; Liu LJ; Zhou Y; Yuan W; Yang M; Liu SX; Luo LY; Chen HP; Xiao YH; Qi Q; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jul; 44(7):1119-1125. PubMed ID: 37482716
    [No Abstract]   [Full Text] [Related]  

  • 15. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
    Manoff SB; Liss C; Caulfield MJ; Marchese RD; Silber J; Boslego J; Romero-Steiner S; Rajam G; Glass NE; Whitney CG; Carlone GM
    J Infect Dis; 2010 Feb; 201(4):525-33. PubMed ID: 20088694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
    Kättström M; Uggla B; Tina E; Kimby E; Norén T; Athlin S
    Vaccine; 2023 May; 41(19):3128-3136. PubMed ID: 37061372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
    Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
    Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.